Who is sponsoring NCT05110872?

NCT05110872 is sponsored by Virginia Polytechnic Institute and State University.

What drugs are being tested in NCT05110872?

Interventions in NCT05110872: Cigarette flavor restricted and e-cigarette flavor restricted, Cigarette flavor restricted and e-cigarette flavor unrestricted, Cigarette flavor unrestricted and e-cigarette flavor restricted, Cigarette flavor unrestricted and e-cigarette flavor unrestricted.

What condition does NCT05110872 study?

NCT05110872 studies Tobacco Use Disorder.

Is NCT05110872 still recruiting?

NCT05110872 is currently completed. Last updated 7 October 2025.

Are results published for NCT05110872?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-10-07 · How we verify

NCT05110872

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cigarette and E-cigarette Flavors Manipulations in the Experimental Tobacco Marketplace

Completed NA Results posted Last updated 7 October 2025

What this trial tests

NA trial testing Cigarette flavor restricted and e-cigarette flavor restricted in Tobacco Use Disorder in 302 participants. Completed in 13 August 2021.

Timeline

26 July 2021

Primary endpoint
13 August 2021

13 August 2021

Quick facts

Lead sponsor	Virginia Polytechnic Institute and State University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	302
Start date	26 July 2021
Primary completion	13 August 2021
Estimated completion	13 August 2021
Sites	1 location across United States

Drugs / interventions tested

Cigarette flavor restricted and e-cigarette flavor restricted
Cigarette flavor restricted and e-cigarette flavor unrestricted
Cigarette flavor unrestricted and e-cigarette flavor restricted
Cigarette flavor unrestricted and e-cigarette flavor unrestricted

Conditions studied

Tobacco Use Disorder — all drugs for Tobacco Use Disorder →

Sponsor

Virginia Polytechnic Institute and State University

Who can join

21 and older, any sex, with Tobacco Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Spent the Budget on E-cigarettes for Each Condition Primary · 1 day

Participants will complete purchasing trials in an Experimental Tobacco Marketplace (ETM) with cigarettes increasing in price. Product availability in the ETM depended on the experimental condition. The average percentage of budget spent on e-cigarettes as a function of the restriction of cigarettes and/or e-cigarettes will be assessed.

Cigarette and E-cigarette Restriction

Group	Value	95% CI
Menthol Cigarette Smokers	10.64	± 1.36
Non-menthol Cigarette Smokers	14.87	± 1.44

Cigarette Restriction

Group	Value	95% CI
Menthol Cigarette Smokers	14.74	± 1.62
Non-menthol Cigarette Smokers	14.65	± 1.38

E-cigarette restriction

Group	Value	95% CI
Menthol Cigarette Smokers	8.20	± 1.17
Non-menthol Cigarette Smokers	15.03	± 1.42

No Restriction on Cigarettes or E-cigarettes

Group	Value	95% CI
Menthol Cigarette Smokers	11.35	± 1.45
Non-menthol Cigarette Smokers	16.07	± 1.47

Spent Budget on Cigarettes for Each Condition Primary · 1 day

Participants will complete purchasing trials in an Experimental Tobacco Marketplace (ETM) with cigarettes increasing in price. Product availability in the ETM depended on the experimental condition. The average percentage of the budget spent on cigarettes as a function of the restriction of cigarettes and/or e-cigarettes will be assessed.

Cigarette and E-cigarette Restriction

Group	Value	95% CI
Menthol Cigarette Smokers	55.04	± 2.56
Non-menthol Cigarette Smokers	65.82	± 2.03

Cigarette Restriction

Group	Value	95% CI
Menthol Cigarette Smokers	53.05	± 2.57
Non-menthol Cigarette Smokers	65.80	± 2.02

E-cigarette Restriction

Group	Value	95% CI
Menthol Cigarette Smokers	73.60	± 2.13
Non-menthol Cigarette Smokers	65.72	± 2.00

No Restriction on Cigarettes or E-cigarettes

Group	Value	95% CI
Menthol Cigarette Smokers	72.05	± 2.14
Non-menthol Cigarette Smokers	65.20	± 2.03

Sponsor's own description

This is a one-session study that participants complete remotely including consent, Experimental Tobacco Marketplace purchases, and assessments to examine the effects of cigarette and e-cigarette flavors on cigarette demand and substitution in the Experimental Tobacco Marketplace.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Restrictions of cigarette and e-cigarette flavor and filter ventilation on demand and substitution in the Experimental Tobacco Marketplace.
Freitas-Lemos R, Tegge AN, Tomlinson DC, Athamneh LN, et al · · 2024 · cited 4× · PMID 39226822 · DOI 10.1016/j.drugalcdep.2024.112422
Selective Reduction of Socioeconomic Disparities in the Experimental Tobacco Marketplace: Effects of Cigarette and E-cigarette Flavor Restrictions.
Freitas-Lemos R, Tegge AN, Shevorykin A, Tomlinson DC, et al · · 2024 · cited 4× · PMID 38817033 · DOI 10.1093/ntr/ntad070
Choice Bundling Increases Valuation of Delayed Losses More Than Gains in Cigarette Smokers.
Stein JS, Brown JM, Tegge AN, Freitas-Lemos R, et al · · 2021 · cited 4× · PMID 35095439 · DOI 10.3389/fnbeh.2021.796502

Verify or expand the search:

Other recruiting trials for Tobacco Use Disorder

Currently open trials in the same condition.

NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
NCT06678672 — Contingency Management for Veteran Smokers Undergoing Major Elective Surgery · NA · recruiting
NCT06006143 — Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2 · Phase 2 · active not recruiting
NCT06883162 — Cannabis-Tobacco Co-Use Treatment Study · Phase 3 · recruiting
NCT06798324 — tDCS Plus Varenicline for Smoking Cessation · Phase 4 · recruiting

Other Virginia Polytechnic Institute and State University trials

Trials by the same sponsor.

NCT07521072 — Testing an Intervention for College Students With Food Insecurity and Binge Eating · EARLY_PHASE1 · not yet recruiting
NCT07042373 — Effects of Tobacco Abuse Liability-dependent Taxes in the ETM · NA · not yet recruiting
NCT07158749 — Generalized and Domain-Specific Episodic Thinking for Smoking Cessation · NA · not yet recruiting
NCT07457710 — Remote Haptic Rehabilitation for Parkinson's Disease · NA · not yet recruiting
NCT05103514 — The Longitudinal Impact of SES and the CNDS on Recovery From SUD · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05110872 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Virginia Polytechnic Institute and State University
Last refreshed: 7 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05110872.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing